EirGenix (6589.TWO) Stock Price

EirGenix Price

CLOSED
51.30
​
Market closed

Revenue has compounded at 48.7% per year over the past 12 years to 1.01 B TWD. EirGenix's net margin stands at -75.7%, down from -2.5% several years earlier.

EirGenix stock price

Access this data via the Eulerpool API

EirGenix business model & stock analysis

EirGenix, Inc. engages in the research and development of biotechnology drugs. The company is headquartered in Taipei, New Taipei. The company went IPO on 2016-11-23. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.

Frequently asked questions about EirGenix

9 analysts currently rate the EirGenix stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect EirGenix to generate revenue of 1.47 B TWD and earnings per share of -1.54 TWD.

Converted at the current exchange rate, the EirGenix share trades at 1.43 EUR (51.30 TWD).

The expected revenue of EirGenix is 1.47 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of EirGenix is -466.03 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of EirGenix is currently -33.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the EirGenix stock.

The price-to-sales ratio (P/S) of EirGenix is currently 10.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the EirGenix stock.

The Eulerpool Quality Score for EirGenix is 3/10.

The ISIN of EirGenix is TW0006589005. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of EirGenix is 6589.TWO. The ticker symbol is used to trade EirGenix shares on the stock exchange.

Fair ValueTerminal
49.25 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
5.91 M TWD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website eirgenix.com
Country
Taiwan
Currency
TWD
Initial public offering
Nov 23, 2016
ISIN
TW0006589005
Cusip
Y22672102
Market capitalization
15.73 B TWDLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-33.31
P/Ee 2027
90.00
P/Se
10.53
EV/EBIT
—
P/B Ratio
1.89
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-8.24 %
Last updated Oct 9, 2026, 7:08 PM

EirGenix Peer Group

EirGenix FIGI

6589:TT (Taipei Stock Exchange) · BBG00F9WQ1D1

All fundamentals and in-depth analysis of EirGenix

Our stock analysis for EirGenix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EirGenix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.